Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

LA-DP Immunopeptidome Divergence Predicts CD4⁺ T-Cell Alloreactivity and Outcome of Hematopoietic Cell Transplantation

Études rétrospectives

Leucémie Myéloïde Aiguë (LMA)

Leucémie Aiguë Lymphoblastique (LAL)

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Peter van Balen & Liesbeth de Wreede

Real-World Use of Post-Transplant Cyclophosphamide (PTCy) for Graft-Vs-Host-Disease (GVHD) Prophylaxis in Transplant Centers

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Outcomes of patients over 70 years treated with brexucabtagene autoleucel for relapsed refractory mantle cell lymphoma: a study from the CTIWP of EBMT

Retrospective Studies

Other myeloid or lymphoid malignancies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Comparison of outcomes of immune-suppression therapy and stem cell transplant using RACE trial data and a registry transplant cohort

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Immunosuppressive Treatment (IST)

Investigateur principal

Simona Iacobelli, Antonio Risitano

Impact of hematological response after Immunosuppressive Treatment on Quality of Life in Aplastic Anemia (subanalysis of the RACE trial)

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Immunosuppressive Treatment (IST)

Investigateur principal

Iris Lommerse, Jennifer Tjon, Stijn Halkes

Efficacy and safety of checkpoint inhibitors after allogeneic hematopoietic cell transplantation in relapsed/refractory classic Hodgkin lymphoma

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Liudmila Fedorova

Efficacité et sécurité des inhibiteurs de points de contrôle immunitaire après transplantation allogénique de cellules souches hématopoïétiques dans le lymphome de Hodgkin classique en rechute/réfractaire

Études rétrospectives

Lymphome non hodgkinien (LNH)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Liudmila Fedorova

Long-term outcomes of PTCy vs. ATG in MRD, MUD, MMUD

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Hélène Schoemans

CVC and anticoagulation survey in HCT and CAR-T

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Retrospective analysis of Autologous and Allogeneic Hematopoietic TRansplantation in Extra Nodal Digestive Peripheral T-cell Lymphoma.

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Olivier TOURNILHAC

Analyse rétrospective des transplantations autologues et allogéniques dans le lymphome périphérique à cellules T extra-nodal digestif

Études rétrospectives

Lymphome non hodgkinien (LNH)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Olivier TOURNILHAC

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic SCT

Retrospective Studies

Chronic Myeloid Leukaemia (CML)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Hugues de Lavallade